Measuring the mind: Assessing the cognitive effects of new compounds for the treatment of schizophrenia There has been considerable recent interest in seeking to develop drugs to rescue cognition in patients with schizophrenia. The academic, pharmaceutical and test development communities have responded to the need for standardized measures of cognitive change for use in studies of Cognitive Impairment Associated with Schizophrenia (CIAS) in a variety of ways. A major impetus was provided by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, which helpfully characterised the cognitive deficits associated with schizophrenia. The MATRICS group also suggested the use of tests from clinical psychology as a means of assessing these key cognitive domains. Other groups have also proposed measures of the MATRICS specified domains. In this presentation we will consider data from trials that have employed the MATRICS Consensus Cognitive Battery (MCCB) as well as those to have employed other cognitive measures. We will also give consideration to the issue of the clinical relevance of cognitive effects and the relationship between cognitive and functional improvement.